These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24671949)

  • 1. In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment.
    Ardeshirpour Y; Chernomordik V; Hassan M; Zielinski R; Capala J; Gandjbakhche A
    Clin Cancer Res; 2014 Jul; 20(13):3531-9. PubMed ID: 24671949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model.
    van de Ven SM; Elias SG; Chan CT; Miao Z; Cheng Z; De A; Gambhir SS
    Clin Cancer Res; 2012 Feb; 18(4):1073-81. PubMed ID: 22235098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging.
    Hassan M; Chernomordik V; Zielinski R; Ardeshirpour Y; Capala J; Gandjbakhche A
    Mol Imaging; 2012 Jun; 11(3):177-86. PubMed ID: 22554482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging.
    Zielinski R; Hassan M; Lyakhov I; Needle D; Chernomordik V; Garcia-Glaessner A; Ardeshirpour Y; Capala J; Gandjbakhche A
    PLoS One; 2012; 7(7):e41016. PubMed ID: 22911732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the impact of HER2 status on the antitumor activity of an HSP90 inhibitor in human tumor xenograft mice using pharmacokinetic-pharmacodynamic modeling.
    Saitoh R; Nagayasu M; Shibahara N; Ono N; Suda A; Kato M; Ishigai M
    Drug Metab Pharmacokinet; 2014; 29(2):185-91. PubMed ID: 24126359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
    Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
    Bull EE; Dote H; Brady KJ; Burgan WE; Carter DJ; Cerra MA; Oswald KA; Hollingshead MG; Camphausen K; Tofilon PJ
    Clin Cancer Res; 2004 Dec; 10(23):8077-84. PubMed ID: 15585643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?
    Arteaga CL
    Clin Cancer Res; 2011 Aug; 17(15):4919-21. PubMed ID: 21670086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
    De Mattos-Arruda L; Cortes J
    Breast; 2012 Aug; 21(4):604-7. PubMed ID: 22560618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
    Martins CD; Da Pieve C; Burley TA; Smith R; Ciobota DM; Allott L; Harrington KJ; Oyen WJG; Smith G; Kramer-Marek G
    Clin Cancer Res; 2018 Apr; 24(8):1853-1865. PubMed ID: 29437790
    [No Abstract]   [Full Text] [Related]  

  • 12. Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy.
    Gee MS; Upadhyay R; Bergquist H; Alencar H; Reynolds F; Maricevich M; Weissleder R; Josephson L; Mahmood U
    Radiology; 2008 Sep; 248(3):925-35. PubMed ID: 18647846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
    Scaltriti M; Serra V; Normant E; Guzman M; Rodriguez O; Lim AR; Slocum KL; West KA; Rodriguez V; Prudkin L; Jimenez J; Aura C; Baselga J
    Mol Cancer Ther; 2011 May; 10(5):817-24. PubMed ID: 21383049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors.
    Ardeshirpour Y; Sackett DL; Knutson JR; Gandjbakhche AH
    EJNMMI Res; 2018 Apr; 8(1):26. PubMed ID: 29619584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
    Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
    Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
    Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
    Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.
    Smith-Jones PM; Solit DB; Akhurst T; Afroze F; Rosen N; Larson SM
    Nat Biotechnol; 2004 Jun; 22(6):701-6. PubMed ID: 15133471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo assessment of HER2 receptor density in HER2-positive tumors by near-infrared imaging, using repeated injections of the fluorescent probe.
    Ardeshirpour Y; Hassan M; Zielinski R; Horton J; Capala J; Gandjbakhche AH; Chernomordik V
    Technol Cancer Res Treat; 2014 Oct; 13(5):427-34. PubMed ID: 24000992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
    Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
    J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.